Smith, RS. The macrophage theory of depression. Med Hypotheses
1991; 35: 298–306.
Maes, M, Bosmans, E, Meltzer, HY, Scharpe, S, Suy, E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?
Am J Psychiatry
1993; 150: 1189–93.
Frommberger, UH, Bauer, J, Haselbauer, P, Fraulin, A, Riemann, D, Berger, M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci
1997; 247: 228–33.
Mikova, O, Yakimova, R, Bosmans, E, Kenis, G, Maes, M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol
2001; 11: 203–8.
Sluzewska, A, Rybakowski, J, Bosmans, E, Sobieska, M, Berghmans, R, Maes, M, et al. Indicators of immune activation in major depression. Psychiatry Res
1996; 64: 161–7.
Berk, M, Wadee, AA, Kuschke, RH, O'Neill-Kerr, A. Acute phase proteins in major depression. J Psychosom Res
1997; 43: 529–34.
Pepys, MB, Baltz, ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol
1983; 34: 141–212.
Deodhar, SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med
1989; 56: 126–30.
Pikhart, H, Hubacek, JA, Kubinova, R, Nicholson, A, Peasey, A, Capkova, N, et al. Depressive symptoms and levels of C-reactive protein: a population-based study. Soc Psychiatry Psychiatr Epidemiol
2009; 44: 217–22.
Ford, DE, Erlinger, TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med
2004; 164: 1010–4.
Panagiotakos, DB, Pitsavos, C, Chrysohoou, C, Tsetsekou, E, Papageorgiou, C, Christodoulou, G, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J
2004; 25: 492–9.
Danner, M, Kasl, SV, Abramson, JL, Vaccarino, V. Association between depression and elevated C-reactive protein. Psychosom Med
2003; 65: 347–56.
Penninx, BW, Kritchevsky, SB, Yaffe, K, Newman, AB, Simonsick, EM, Rubin, S, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry
2003; 54: 566–72.
Kop, WJ, Gottdiener, JS, Tangen, CM, Fried, LP, McBurnie, MA, Walston, J, et al. Inflammation and coagulation factors in persons 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol
2002; 89: 419–24.
Bluthe, RM, Michaud, B, Poli, V, Dantzer, R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav
2000; 70: 367–73.
Dutcher, J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park)
2002; 16: 4–10.
Dutcher, J. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma. Oncology (Williston Park)
2002; 16: 3.
Dutcher, JP, Logan, T, Gordon, M, Sosman, J, Weiss, G, Margolin, K, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res
2000; 6: 3442–50.
Dell'Osso, L, Pini, S, Maggi, L, Rucci, P, Del Debbio, A, Carlini, M, et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res
2007; 62: 349–55.
van den Biggelaar, AH, Gussekloo, J, de Craen, AJ, Frolich, M, Stek, ML, van der Mast, RC, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol
2007; 42: 693–701.
Milaneschi, Y, Corsi, AM, Penninx, BW, Bandinelli, S, Guralnik, JM, Ferrucci, L. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI Study. Biol Psychiatry
2009; 65: 973–8.
Janssen, J, Beekman, AT, Comijs, HC, Deeg, DJ, Heeren, TJ. Late-life depression: the differences between early- and late-onset illness in a community-based sample. Int J Geriatr Psychiatry
2006; 21: 86–93.
Henry, MJ, Pasco, JA, Nicholson, GC, Seeman, E, Kotowicz, MA. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom
2000; 3: 261–8.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Research Version, Non-patient Edition (SCID–I/NP). Biometrics Research, New York State Psychiatric Institute, 2002.
Korn, EL, Graubard, BI, Midthune, D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol
1997; 145: 72–80.
Visser, M, Bouter, LM, McQuillan, GM, Wener, MH, Harris, TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA
1999; 282: 2131–5.
Hak, AE, Stehouwer, CD, Bots, ML, Polderman, KH, Schalkwijk, CG, Westendorp, IC, et al. Associations of C-reactive protein with measures of adiposity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol
1999; 19: 1986–91.
Yudkin, JS, Stehouwer, CD, Emeis, JJ, Coppack, SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?
Arterioscler Thromb Vasc Biol
1999; 19: 972–8.
Lemieux, I, Pascot, A, Prud'homme, D, Almeras, N, Bogaty, P, Nadeau, A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol
2001; 21: 961–7.
Raitakari, M, Mansikkaniemi, K, Marniemi, J, Viikari, JS, Raitakari, OT. Distribution and determinants of serum high-sensitive C-reactive protein in apopulation of young adults: the Cardiovascular Risk in Young Finns Study. J Intern Med
2005; 258: 428–34.
Williams, LJ, Pasco, JA, Henry, MJ, Jacka, FN, Dodd, S, Nicholson, GC, et al. Lifetime psychiatric disorders and body composition: a population-based study. J Affect Disord
2009; 118: 173–9.
Carpenter, KM, Hasin, DS, Allison, DB, Faith, MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health
2000; 90: 251–7.
Kloiber, S, Ising, M, Reppermund, S, Horstmann, S, Dose, T, Majer, M, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry
2007; 62: 321–6.
Reichenberg, A, Yirmiya, R, Schuld, A, Kraus, T, Haack, M, Morag, A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry
2001; 58: 445–52.
Tiemeier, H, Hofman, A, van Tuijl, HR, Kiliaan, AJ, Meijer, J, Breteler, MM. Inflammatory proteins and depression in the elderly. Epidemiology
2003; 14: 103–7.
Kuo, HK, Yen, CJ, Chang, CH, Kuo, CK, Chen, JH, Sorond, F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol
2005; 4: 371–80.
Berk, M, Ng, F, Dean, O, Dodd, S, Bush, AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci
2008; 29: 346–51.
Berk, M. Oxidative biology: new intervention opportunities in psychiatry. Acta Neuropsychiatrica
2007; 19: 259–60.
Galecki, P, Szemraj, J, Bienkiewicz, M, Zboralski, K, Galecka, E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol
2009; 24: 277–86.
Wei, YC, Zhou, FL, He, DL, Bai, JR, Hui, LY, Wang, XY, et al. The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma. J Psychosom Res
2009; 66: 259–66.
Barry, S, Clarke, G, Scully, P, Dinan, TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol
2009; 23: 287–94.
Pasco, JA, Williams, LJ, Jacka, FN, Ng, F, Henry, MJ, Nicholson, GC, et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br J Psychiatry
2008; 193: 322–6.
Hamalainen, J, Kaprio, J, Isometsa, E, Heikkinen, M, Poikolainen, K, Lindeman, S, et al. Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. J Epidemiol Community Health
2001; 55: 573–6.
Malhi, GS, Berk, M. Does dopamine dysfunction drive depression?
Acta Psychiatr Scand
2007; 115 (suppl 433): 116–24.
Kangavari, S, Matetzky, S, Shah, PK, Yano, J, Chyu, KY, Fishbein, MC, et al. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J Cardiovasc Pharmacol Ther
2004; 9: 291–8.
Blumenfeld, Z, Boulman, N, Leiba, R, Siegler, E, Shachar, S, Linn, R, et al. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Clin Lab Invest
2007; 67: 257–63.
Danese, A, Pariante, CM, Caspi, A, Taylor, A, Poulton, R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA
2007; 104: 1319–24.
Danese, A, Moffitt, TE, Pariante, CM, Ambler, A, Poulton, R, Caspi, A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry
2008; 65: 409–15.
Yuan, G, Zhou, L, Tang, J, Yang, Y, Gu, W, Li, F, et al. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract
2006; 72: 244–50.
Danesh, J, Wheeler, JG, Hirschfield, GM, Eda, S, Eiriksdottir, G, Rumley, A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med
2004; 350: 1387–97.
Pasco, JA, Kotowicz, MA, Henry, MJ, Nicholson, GC, Spilsbury, HJ, Box, JD, et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA
2006; 296: 1353–5.
Nilsson, K, Gustafson, L, Hultberg, B. C-reactive protein: vascular risk marker in elderly patients with mental illness. Dement Geriatr Cogn Disord
2008; 26: 251–6.